Investing.com -- GlaxoSmithKline (NYSE: GSK) Bioc announced its financial results for the second quarter, reporting a consolidated net profit attributable of EGP 5.9 million. The company also reported ...

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and ...

DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb from an estimated USD 34.8 billion in 2025 to USD 53.6 billion by 2035. This ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.

Get comprehensive insights into the Uncomplicated Urinary Tract Infections (UTIs) pipeline with this 2025 report. It details 4+ companies and 5+ pipeline drugs, covering drug profiles, therapeutic ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...